Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577001 | 0.83 | TRPA1 (0.51) | TRPA1BACE1CYP3A4ALOX15 | |
| SCHEMBL1726796 | 0.80 | TRPA1 (0.56) | TRPA1BACE1 | |
| Dibenzo[B,F][1,4]Thiazepine SCHEMBL696578 | 0.71 | TRPA1 (1.00) | TRPA1BACE1CYP3A4ALOX15 | |
| SCHEMBL9232229 | 0.70 | TRPA1 (0.55) | TRPA1CYP3A4ALOX15CASP1CASP7 | |
| SCHEMBL1568752 | 0.70 | TRPA1 (0.49) | TRPA1BACE1 | |
| SCHEMBL1132785 | 0.69 | TRPA1 (0.44) | TRPA1CYP3A4ALOX15SMN1; SMN2 | |
| SCHEMBL1568098 | 0.68 | DRD2 (0.51) | TRPA1 | |
| SCHEMBL4787337 | 0.68 | DRD2 (0.44) | TRPA1 | |
| SCHEMBL30004363 | 0.68 | TRPA1 (0.50) | TRPA1 | |
| SCHEMBL5259226 | 0.68 | KMT2A (0.40) | CYP3A4ALOX15CASP1CASP7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129402-B2 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-06 | — | — | US | disclosed |
| US-20110092483-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-04-21 | — | — | US | disclosed |
| US-20060172337-A1 | Screening molecules with anti-prion activity: kits, methods and screened molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092483-A1 | SCREENING MOLECULES WITH ANTI-PRION ACTIVITY: KITS, METHODS AND SCREENED MOLECULES | ATXN2L, ATXN10, CLN6 | TRPA1 4766/4885BACE1 2428/4885CYP3A4 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.